Annual CFO
-$43.80 M
+$48.66 M+52.63%
31 December 2023
Summary:
Monte Rosa Therapeutics annual cash flow from operations is currently -$43.80 million, with the most recent change of +$48.66 million (+52.63%) on 31 December 2023. During the last 3 years, it has fallen by -$20.75 million (-90.01%). GLUE annual CFO is now -609.57% below its all-time high of -$6.17 million, reached on 31 December 2019.GLUE Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$20.99 M
+$6.77 M+24.39%
30 September 2024
Summary:
Monte Rosa Therapeutics quarterly cash flow from operations is currently -$20.99 million, with the most recent change of +$6.77 million (+24.39%) on 30 September 2024. Over the past year, it has increased by +$3.71 million (+15.02%). GLUE quarterly CFO is now -170.84% below its all-time high of $29.63 million, reached on 31 December 2023.GLUE Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$57.29 M
+$3.71 M+6.08%
30 September 2024
Summary:
Monte Rosa Therapeutics TTM cash flow from operations is currently -$57.29 million, with the most recent change of +$3.71 million (+6.08%) on 30 September 2024. Over the past year, it has increased by +$40.10 million (+41.18%). GLUE TTM CFO is now -1597.04% below its all-time high of -$3.38 million, reached on 31 March 2020.GLUE TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GLUE Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +52.6% | +15.0% | +41.2% |
| 3 y3 years | -90.0% | -18.0% | -6.6% |
| 5 y5 years | - | - | - |
GLUE Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -90.0% | +52.6% | -170.8% | +45.0% | -30.8% | +41.2% |
| 5 y | 5 years | -609.6% | +52.6% | -170.8% | +45.0% | -1597.0% | +41.2% |
| alltime | all time | -609.6% | +52.6% | -170.8% | +45.0% | -1597.0% | +41.2% |
Monte Rosa Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$20.99 M(-24.4%) | -$57.29 M(-6.1%) |
| June 2024 | - | -$27.77 M(-27.2%) | -$61.00 M(+4.2%) |
| Mar 2024 | - | -$38.16 M(-228.8%) | -$58.56 M(+33.7%) |
| Dec 2023 | -$43.80 M(-52.6%) | $29.63 M(-219.9%) | -$43.80 M(-55.0%) |
| Sept 2023 | - | -$24.71 M(-2.4%) | -$97.40 M(+4.4%) |
| June 2023 | - | -$25.32 M(+8.2%) | -$93.29 M(+5.5%) |
| Mar 2023 | - | -$23.41 M(-2.3%) | -$88.47 M(-4.3%) |
| Dec 2022 | -$92.47 M | -$23.96 M(+16.3%) | -$92.47 M(+11.8%) |
| Sept 2022 | - | -$20.60 M(+0.5%) | -$82.68 M(+3.5%) |
| June 2022 | - | -$20.50 M(-25.2%) | -$79.87 M(+9.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$27.40 M(+93.4%) | -$72.95 M(+22.9%) |
| Dec 2021 | -$59.36 M(+157.5%) | -$14.17 M(-20.4%) | -$59.36 M(+10.4%) |
| Sept 2021 | - | -$17.79 M(+31.0%) | -$53.77 M(+25.4%) |
| June 2021 | - | -$13.58 M(-1.7%) | -$42.86 M(+28.0%) |
| Mar 2021 | - | -$13.81 M(+61.1%) | -$33.49 M(+45.3%) |
| Dec 2020 | -$23.05 M(+273.4%) | -$8.57 M(+24.4%) | -$23.05 M(+59.2%) |
| Sept 2020 | - | -$6.89 M(+63.6%) | -$14.48 M(+90.8%) |
| June 2020 | - | -$4.21 M(+24.8%) | -$7.59 M(+124.8%) |
| Mar 2020 | - | -$3.38 M | -$3.38 M |
| Dec 2019 | -$6.17 M | - | - |
FAQ
- What is Monte Rosa Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics annual CFO year-on-year change?
- What is Monte Rosa Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics quarterly CFO year-on-year change?
- What is Monte Rosa Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics TTM CFO year-on-year change?
What is Monte Rosa Therapeutics annual cash flow from operations?
The current annual CFO of GLUE is -$43.80 M
What is the all time high annual CFO for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high annual cash flow from operations is -$6.17 M
What is Monte Rosa Therapeutics annual CFO year-on-year change?
Over the past year, GLUE annual cash flow from operations has changed by +$48.66 M (+52.63%)
What is Monte Rosa Therapeutics quarterly cash flow from operations?
The current quarterly CFO of GLUE is -$20.99 M
What is the all time high quarterly CFO for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high quarterly cash flow from operations is $29.63 M
What is Monte Rosa Therapeutics quarterly CFO year-on-year change?
Over the past year, GLUE quarterly cash flow from operations has changed by +$3.71 M (+15.02%)
What is Monte Rosa Therapeutics TTM cash flow from operations?
The current TTM CFO of GLUE is -$57.29 M
What is the all time high TTM CFO for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high TTM cash flow from operations is -$3.38 M
What is Monte Rosa Therapeutics TTM CFO year-on-year change?
Over the past year, GLUE TTM cash flow from operations has changed by +$40.10 M (+41.18%)